Evidence map›Paper›PMID 28931062›Full record

ArticlePloS one2017

Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.

Magdalena Rosińska, Natalia Parda, Agnieszka Kołakowska, Paulina Godzik, Karolina Zakrzewska, Kazimierz Madaliński, Andrzej Zieliński, Anna Boguradzka, Rafał Gierczyński, Małgorzata Stępień

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Perspectives of hepatitis C virus (HCV) elimination in Poland.Clinical and experimental hepatology · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Magdalena RosińskaDepartment of Epidemiology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.ORCID http://orcid.org/0000-0002-6256-7809
Natalia PardaDepartment of Epidemiology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Agnieszka KołakowskaDepartment of Virology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Paulina GodzikDepartment of Virology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Karolina ZakrzewskaDepartment of Epidemiology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Kazimierz MadalińskiDepartment of Virology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Andrzej ZielińskiDepartment of Epidemiology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Anna BoguradzkaDepartment of Family Practice, Centre of Postgraduate Medical Education, Warsaw, Poland.
Rafał GierczyńskiDepartment of Bacteriology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Małgorzata StępieńDepartment of Epidemiology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy · PLPostgraduate School of Molecular Medicine · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsThere is a considerable burden of hepatitis C in Europe related to the lack of prompt diagnosis. We aimed to estimate the prevalence and related risk factors of HCV infections by the stages of liver fibrosis, using non-invasive methods, to understand testing needs in Poland.

methodsA cross-sectional study was conducted in 2012-2016 adopting a stratified random sampling of primary health care units followed by systematic sampling of patients within each unit. Study participants filled a questionnaire and donated blood for laboratory HCV testing. Additionally, the results of liver function tests and platelet count were collected to calculate APRI and FIB-4 scores. Cases were classified according to the level of fibrosis: 'significant fibrosis' (APRI≥0.7 or FIB4≥1.45) and 'no significant fibrosis' (APRI<0.7 and FIB4<1.45).

resultsOf 21 875 study participants, 102 were HCV-RNA positive. Prevalence of HCV infections and significant fibrosis was estimated at 0.47% (95% CI 0.38% - 0.57%) and 0.12% (0.08% - 0.17%), respectively. Cases with significant fibrosis accounted for 51.6% (33.4%-69.9%) in men and 34.4% (17.3%-51.4%) in women. There was no correlation between the HCV prevalence and age. Blood transfusion prior to 1992 strongly predicted significant fibrosis as did the history of injecting drug use (IDU) and ever having an HCV-infected sexual partner in men and caesarean sections in women. Factors associated with HCV infection without significant fibrosis were tattooing in men and younger age in women. We acknowledge limited possibility to study the associations between IDU and ever having HCV-infected sexual partner, given small sample sizes for these exposures.

conclusionsAs no clear birth cohort affected by HCV could be identified, risk factor-based screening in the general population should be considered, taking into account the association between the increased risk of liver fibrosis and the history of transfusion prior to 1992 and caesarean sections.

Indexed as

AdultCross-Sectional StudiesFemaleHepatitis CHumansLiver CirrhosisMaleMiddle AgedPolandPrevalenceRisk FactorsTattooingTransfusion Reaction

Identifiers

PMID28931062
PMCPMC5607182
OpenAlexW2754780539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.